Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2012 Nov-Dec;32(6):664-6.
doi: 10.3747/pdi.2011.00307.

Interferon alpha concentrations in blood and peritoneal fluid during treatment for hepatitis C

C Smirne, R Minisini, M E Burlone, E Ceriani, F Corlianò, G Occhino, M Pirisi
Case Reports

Interferon alpha concentrations in blood and peritoneal fluid during treatment for hepatitis C

C Smirne et al. Perit Dial Int. 2012 Nov-Dec.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
— Changes of serum interferon (IFN) alpha concentration (filled circles) in relation to variations in peritoneal fluid IFN concentration, serum hepatitis C virus (HCV) RNA. Modifications of IFN dose (arrows) and neutrophil count (filled triangles) during IFN treatment are also shown. + = detectable; - = undetectable; PF = peritoneal fluid.
See this image and copyright information in PMC

References

    1. Terrault NA, Adey DB. The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment. Clin J Am Soc Nephrol 2007; 2:563–75 - PubMed
    1. Rostaing L, Chatelut E, Payen JL, Izopet J, Thalamas C, Ton-That H, et al. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 1998; 9:2344–8 - PubMed
    1. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008; (109):S1–99 - PubMed
    1. Ghany MG, Strader DB, Thomas DL, Seeff LB. on behalf of the American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335–74 - PMC - PubMed
    1. Chan TM, Ho SK, Tang CS, Tse KC, Lam MF, Lai KN, et al. Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection. Nephrology (Carlton) 2007; 12:11–17 - PubMed

MeSH terms

LinkOut - more resources